A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801)
A Randomized Study of Adjuvant vs NeoAdjuvant Pembrolizumab for Clinically Detectable Stage III-IV High Risk Melanoma (S1801)
Trial Category:
Melanoma
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
